TransMedics Group, Inc. (NASDAQ:TMDX) VP John F. Carey Sells 3,360 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) VP John F. Carey sold 3,360 shares of TransMedics Group stock in a transaction that occurred on Monday, April 5th. The shares were sold at an average price of $36.87, for a total transaction of $123,883.20. Following the transaction, the vice president now directly owns 3,360 shares of the company’s stock, valued at $123,883.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

John F. Carey also recently made the following trade(s):

  • On Thursday, March 11th, John F. Carey sold 3,200 shares of TransMedics Group stock. The shares were sold at an average price of $37.50, for a total transaction of $120,000.00.

Shares of NASDAQ TMDX opened at $33.50 on Thursday. The firm has a market cap of $916.90 million, a PE ratio of -23.93 and a beta of 2.16. The firm has a fifty day moving average of $37.97 and a 200 day moving average of $22.38. The company has a debt-to-equity ratio of 0.32, a quick ratio of 10.36 and a current ratio of 11.31. TransMedics Group, Inc. has a one year low of $11.51 and a one year high of $49.50.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, March 1st. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. TransMedics Group had a negative net margin of 131.35% and a negative return on equity of 38.95%. On average, equities analysts predict that TransMedics Group, Inc. will post -1.18 EPS for the current fiscal year.

Several equities analysts have recently weighed in on TMDX shares. Canaccord Genuity lifted their target price on shares of TransMedics Group from $46.00 to $79.00 and gave the company a “buy” rating in a report on Monday, March 15th. Morgan Stanley lifted their target price on shares of TransMedics Group from $16.00 to $38.00 and gave the company an “equal weight” rating in a report on Tuesday, March 9th. Oppenheimer lifted their target price on shares of TransMedics Group from $25.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, March 2nd. Zacks Investment Research raised shares of TransMedics Group from a “sell” rating to a “hold” rating in a report on Saturday, April 3rd. Finally, Cowen boosted their price target on shares of TransMedics Group from $44.00 to $49.00 and gave the stock an “outperform” rating in a report on Monday, March 29th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $41.00.

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. California Public Employees Retirement System boosted its stake in TransMedics Group by 30.5% during the 3rd quarter. California Public Employees Retirement System now owns 52,200 shares of the company’s stock worth $719,000 after purchasing an additional 12,200 shares during the last quarter. BlackRock Inc. boosted its stake in TransMedics Group by 19.6% during the 3rd quarter. BlackRock Inc. now owns 1,567,596 shares of the company’s stock worth $21,602,000 after purchasing an additional 257,082 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in TransMedics Group by 12.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 13,838 shares of the company’s stock worth $191,000 after purchasing an additional 1,546 shares during the last quarter. State Street Corp boosted its stake in TransMedics Group by 8.7% during the 3rd quarter. State Street Corp now owns 338,228 shares of the company’s stock worth $4,661,000 after purchasing an additional 27,133 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in TransMedics Group by 120.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 160,471 shares of the company’s stock worth $2,212,000 after purchasing an additional 87,548 shares during the last quarter. 76.68% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Story: Basic Economics

Insider Buying and Selling by Quarter for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.